study of cbx-12 in subjects with advanced or metastatic refractory solid tumors

Conditions: Solid Tumor, Adult; Epithelial Ovarian Cancer; Small Cell Lung Carcinoma; Breast Cancer; Colorectal Cancer; Pancreas Cancer; Appendix Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Esophagus Cancer; Urothelial Carcinoma; Sarcoma

Summary: this is a first-in-human, phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (pk), and biomarker study of cbx-12 in subjects with advanced or metastatic refractory solid tumors.

phase 1 is the dose-escalation portion of the study in which the safety and tolerability of three dosing schedules of cbx-12 will be evaluated. subjects in part a will be treated with cbx-12 on a daily x 5 every 3 weeks schedule (treatment in part a was discontinued in october 2021). subjects in phase 1 part b will be treated with cbx-12 on a daily x 3 every 3 weeks schedule. subjects in phase 1 part c will be treated with cbx-12 once weekly. subjects in phase 1 modified part b will be treated with cbx-12 once every 3 weeks. for all parts in phase 1, after all subjects in a cohort have completed treatment through the dlt period or discontinued treatment due to a dlt, the src, composed of the investigators who have enrolled subjects in the current cohort(s), the study medical monitor and ad hoc members (e.g., other investigators, a statistician) as needed, will review all available safety data, including dlts and all available pk data for that cohort and make dose-level recommendations. once the recommended phase 2 dose (rp2d) has been established in part b, part c and modified part b, phase 2 expansion cohorts may open.

Eligibility criteria:
key inclusion criteria: * subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. subject's prior treatment should include all approved regimens that have demonstrated a survival advantage for the subject's disease, stage, and line of therapy. * has measurable disease per recist 1.1. * an adequate tumor sample must be available from core needle biopsies obtained during the screening period and following the subject's most recent systemic therapy. * agrees to an on-treatment biopsy preferably of the same lesion from which the pre-cbx-12 treatment sample was obtained as long as the investigator determines such biopsy can be performed with acceptable safety. (removed amd 4, date 31-mar-2023) exclusion criteria: * cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy less than or equal to 3 weeks prior to the first dose of cbx-12. the interval may be reduced to 2 weeks for bone only radiation therapy or investigational agents not expected to be associated with adverse events (aes) after 2 weeks of last administration, with medical monitor approval. * small-molecule kinase inhibitors or hormonal agents less than or equal to 14 days prior to the first dose of cbx-12. * subjects who are currently receiving any other anti cancer or investigational agent(s). * clinically significant intercurrent disease. * subjects with primary central nervous system (cns) tumors or clinically active cns metastases or carcinomatous meningitis. subjects with stable brain metastasis may be enrolled with medical monitor approval.

Keywords: sclc small cell lung cancer ovarian breast appendix colorectal pancreatic nsclc sarcoma